RxDoctor Payments Data

Yelena Magay

Family · Abbeville, LANPI 1790198208

Payments from drug & device makers

$8,435in general payments, 2019–2025

Across 63 payments — averaging $133.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Vertex$2K
  • AstraZeneca$812
  • Vifor Pharma, Inc.$244
  • Sanofi$202
  • Travere Therapeutics, Inc.$173
  • plus $395 from 6 others

What the payments were for

  • Consulting fees$2,42329%
  • Speaking & faculty fees$2,50030%
  • Travel & lodging$1,42417%
  • Food & beverage$1,92423%
  • Education$1642%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,435 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$30,015
Medicare patients
186
Services billed
376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol137$147,545
VeltassaPatiromer Calcium Sorbitex59$99,584
JardianceEmpagliflozin27$35,958
OzempicSemaglutide23$21,918
LokelmaSodium Zirconium Cyclosilicate20$17,395
LinzessLinaclotide13$11,995
Repatha SureclickEvolocumab12$6,766
Potassium Chloride125$2,291
Calcitriol108$1,988
Amlodipine Besylate226$1,766
Torsemide118$1,587
Losartan Potassium119$1,197
Allopurinol138$1,048
Novolin R FlexpenInsulin Regular, Human11$945
Hydralazine Hcl69$901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$812$164,940157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Abbeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →